The *Drosophila* neuregulin homolog Vein mediates inductive interactions between myotubes and their epidermal attachment cells

Talia Yarnitzky, Li Min, and Talila Volk¹

Department of Molecular Genetics, The Weizmann Institute of Science, 76100 Rehovot, Israel

Inductive interactions between cells of distinct fates underlie the basis for morphogenesis and organogenesis across species. In the *Drosophila* embryo, somatic myotubes form specific interactions with their epidermal muscle attachment (EMA) cells. The establishment of these interactions is a first step toward further differentiation of the EMA cells into elongated tendon cells containing an organized array of microtubules and microfilaments. Here we show that the molecular signal for terminal differentiation of tendon cells is the secreted *Drosophila* neuregulin-like growth factor Vein produced by the myotubes. Although *vein* mRNA is produced by all of the myotubes, Vein protein is secreted and accumulates specifically at the muscle-tendon cell junctional site. In loss-of-function *vein* mutant embryos, muscle-dependent differentiation of tendon cells, measured by the level of expression of specific markers (Delilah and $\beta 1$ tubulin) is blocked. When Vein is expressed in ectopic ectodermal cells, it induces the ectopic expression of these genes. Our results favor the possibility that the *Drosophila* EGF receptor DER/Egfr expressed by the EMA cells functions as a receptor for Vein. We show that Vein/Egfr binding activates the Ras pathway in the EMA cells leading to the transcription of the tendon-specific genes, *stripe*, *delilah*, and $\beta 1$ tubulin. In *Egfr*^{1F26} mutant embryos that lack functional Egfr expression, the levels of Delilah and $\beta 1$ tubulin are very low. In addition, the ability of ectopic Vein to induce the expression of Delilah and $\beta 1$ tubulin depends on the presence of functional Egfrs. Finally, activation of the Egfr signaling pathway by either ectopically secreted Spitz, or activated Ras, leads to the ectopic expression of Delilah. These results suggest that inductive interactions between myotubes and their epidermal muscle attachment cells are initiated by the binding of Vein, to the Egfr on the surface of EMA cells.

[Key Words: Muscle; *Drosophila*; mesoderm; epidermal muscle attachment cell; receptor tyrosine kinase; Egfr/DER; Vein; neuregulin]

Received June 24, 1997; revised version accepted August 8, 1997.

Organogenesis is a multistep process, in which, at various stages of development, a defined set of cells influences the differentiation of other nearby cell populations to form tissues and organs. The basis for organ morphogenesis stems from inductive interactions occurring continuously between cells of epithelial and mesenchymal origin. Often, the mesenchyme-derived cells serve as the source for secreted signals that affect the state of differentiation of the neighboring target epithelial cells (Birchmeier et al. 1995).

The differentiation of tendon cells and the formation of muscle-tendon interactions represent an attractive model system to study the nature and hierarchy of molecular and cellular instructive interactions between dis-

tinct cell types that are responsible for the correct connections of body musculature to the skeleton. Here too, equivalent instructive interactions between distinct cell types, including muscles, tendon cells, and bones may regulate the process.

Muscle-tendon interactions in *Drosophila* occur during development of the embryo as well as the adult fly. In both processes myotubes migrate and bind specifically to their attachment cells. The larval somatic muscle tissue develops from mesodermal cells in the anterior compartment of mesodermal segments, determined by autonomous pair-rule gene activity in the mesoderm (Azpiazu et al. 1996). These cells express high levels of the basic helix-loop-helix (bHLH) protein, Twist (Baylies and Bate 1996). The different somatic muscles are formed by an array of 30 different types of myotubes that develop, through the second half of embryonic development, in close proximity to the basal surfaces of the epidermis

¹Corresponding author.
E-MAIL lgvolk@wiccmail.weizmann.ac.il; FAX 972-8-9344108.

(Bate 1990). The identity of each of these somatic myotubes is thought to be determined by inductive patterning mechanisms that define a single founder cell with a given specificity (Bate 1993; Baker and Schubiger 1995; Rushton et al. 1995). The founder cell then fuses to somatic mesodermal cells that, upon fusion, acquire the specificity of the primary founder cell. The specificity of the fused myotube, manifested by a distinct pattern of gene expression, determines the spatial and temporal development of a given myotube, the number of myoblasts to be fused, and the polarity of the fused myotube (Bate 1993; Abmayr et al. 1995). During extension, the myotube sends elongated filopodia at its leading edge, which facilitate its pathfinding toward the epidermal attachment cells (Bate 1990).

The final targeting of the muscle toward its specific epidermal muscle attachment (EMA) cells depends on these target cells (Volk and VijayRaghavan 1994). The initial differentiation of the EMA cells is induced by the activity of *Stripe*, an early growth response (EGR)-like putative transcription factor (Lee et al. 1995) expressed specifically in the EMA cells. *Stripe* is necessary and sufficient for the induction of EMA cell-specific genes including *groovin*, *alien*, and *delilah* and, in addition, positively autoregulates its own transcription. In *stripe* mutant embryos all of the characteristic EMA-specific genes are not expressed, and the muscle pattern is significantly deranged. Ectopic expression of *Stripe* induces ectopic expression of the EMA-specific genes in all of the tissues tested (Frommer et al. 1996; Becker et al. 1997). *Groovin*, a large membrane-associated extracellular protein may mediate adhesion between the muscles and their EMA cells (D. Strumpf and T. Volk, unpubl.). The function of *Delilah*, a bHLH protein characteristic of the EMA cells (Armand et al. 1994), as well as the function of *Alien* [a protein with homology to the human *TRIP15* gene, which interacts with vertebrate thyroid receptor (Goubaud et al. 1996)], are yet to be elucidated. The EMA cells attract and direct the leading edge of the myotube toward its target attachment cells. Specific adhesion between the myotube and the epidermal attachment cells is followed by the formation of extensive adherens-type junctions between the two cell types, mediated by the integrin receptors (Tepass and Hartenstein 1994).

Recent evidence suggests that there are two waves of gene expression in the EMA cells (Becker et al. 1997). The first wave is muscle independent and results from the initial induction of *stripe* in the future tendon cells. The second wave maintains *Stripe* and *Groovin* expression only in EMA cells to which myotubes are connected and, hence, is defined as muscle-dependent regulation of gene expression in these cells. The expression of *Stripe* and *Groovin* in the EMA cells that are not bound to muscles gradually diminishes. Recently, Buttgerit et al. (1996) reported that the expression of $\beta 1$ tubulin, a structural protein characteristic of tendon cells during their terminal differentiation, depends on muscle insertion. These observations suggest that the establishment of EMA-muscle cell interactions is a prerequisite for ter-

минаl differentiation of the tendon-like cells, manifested by the expression of specific genes in these cells.

This paper elucidates the molecular mechanism mediating the inductive interactions between muscles and their specific attachment cells, responsible for terminal differentiation of the EMA cells into tendon cells. We show that muscle-dependent terminal differentiation of tendon cells is induced by activation of the *Drosophila* epidermal growth factor (EGF)-like receptor (Egfr/DER) in the EMA cells, by the neuregulin-like growth factor Vein secreted from the muscle cells.

Results

Elevated levels of Delilah and $\beta 1$ tubulin are induced in the EMA cells as a result of muscle binding

Targeting of the myotube to encounter its counterpart muscle attachment cell in the epidermis is achieved through molecular cross talk between the two cell types. We showed previously that *Stripe* is the key factor in the induction of EMA cell fate determination (Frommer et al. 1996; Becker et al. 1997). *Stripe* is initially expressed in ectodermal cells, from which a subset of cells will develop into tendon cells. Although the initial expression of *Stripe* precedes muscle binding and appears to be independent of signals coming from the muscles, the maintenance of *Stripe* expression is actively induced only in cells that are bound to muscles.

To further analyze the dependence of gene expression in the EMA cells on muscle binding, we examined the timing of gene expression of typical EMA cell-specific genes, relative to the muscle binding process. Two classes of genes were identified: *Groovin* and *Alien* follow the temporal and spatial expression of *Stripe* throughout embryonic development, whereas *Delilah* and $\beta 1$ tubulin expression in embryonic stages 12–14 is relatively low and becomes significantly elevated in embryos at stage 16 and beyond, when binding of somatic muscles is established (Fig. 1A–D). In *heartless* mutant embryos [induced by expressing the extracellular domain of Heartless, dominant-negative (DN)-Htl, under the upstream activating sequence (UAS)/Gal4 system] some of the muscles are missing and *Delilah* and $\beta 1$ tubulin expression is detectable only in those EMA cells that are bound to muscles (Fig. 1E,F). Thus, although the initial expression of *Delilah* is muscle independent (Armand et al. 1994), it appears that muscle binding induces a significant elevation in *Delilah* expression in the EMA cells (Fig. 1). $\beta 1$ tubulin expression is also significantly elevated following muscle binding (this study; Buttgerit et al. 1996).

Thus, in the following experiments high expression of *Delilah* and $\beta 1$ tubulin was taken as a marker for muscle-dependent gene expression within the tendon cells.

Vein mutant embryos show abnormal differentiation of muscle attachment cells

To identify genes involved in the process of muscle-

Figure 1. Muscle-independent, and muscle-dependent expression of Delilah and $\beta 1$ tubulin. Wild-type embryos at stage 12 (A,C) or stage 16 (B,D) were stained with anti-Delilah antibody (A,B) or hybridized with a $\beta 1$ tubulin antisense probe (C,D). At stage 12 of embryonic development, somatic muscles are not yet connected to their EMA cells, and the expression of Delilah and $\beta 1$ tubulin is weak, relative to the strong expression of both markers in embryos at stage 16 when binding of somatic myotubes has been established. In mutant embryos carrying UAS-DN-Htl, and HS-Gal4 (Gal4 under a heat shock promoter), which were heat-shocked at 4–5 hr after egg laying, some of the muscles are missing (E,F). Embryos were double-labeled for Delilah and Myosin (E), or hybridized with a $\beta 1$ tubulin probe (F). Note that the absence of somatic muscles leads to reduced expression of Delilah and $\beta 1$ tubulin. Arrows mark chordotonals; arrowheads in E and F mark regions in which Delilah or $\beta 1$ tubulin expression is abnormal.

EMA cell interactions, we screened a collection of lethal P-element mutations (Karpen and Spradling 1992) and selected a mutant strain (P1749) that exhibits an abnormal muscle phenotype. The myotubes of P1749 mutant embryos are elongated and continuously send filopodia in random directions. This phenotype is most prominent in the ventral oblique muscles and in some dorsal longitudinal muscles (Fig. 2B). The ventral longitudinal

muscles are less affected. The overall pattern of the mesoderm in P1749 mutant embryos at earlier stages of development, including segregation into different mesodermal tissues and subdivision of the somatic mesoderm, appears to be close to normal, although some slight aberrations are observed. However, the expression of the typical epidermal muscle attachment-specific genes in P1749 mutant embryos is abnormal. Although

Figure 2. Somatic muscles and tendon cells are defective in *vein* mutant embryos. Wild-type (A,C,E) and *vein* mutant (B,D,F) embryos were stained with anti-Myosin antibody (A,B), double-labeled with anti-Myosin (green), and anti-Delilah (red) antibody (C,D), and hybridized with a $\beta 1$ tubulin antisense probe (E,F). Notice that the somatic myotubes in the *vein* mutant embryo send elongated random filopodia (black arrows in B) and that the expression of Delilah or $\beta 1$ tubulin in the tendon cells is significantly reduced (cf. white arrows in D and F to C and E, respectively). Arrowheads in C, D, E, and F show a high level of Delilah and $\beta 1$ tubulin expression in the chordotonal organs (ch).

the levels of Stripe and Groovin do not show significant alterations, the levels of Delilah and $\beta 1$ tubulin are significantly reduced (Fig. 2D,F). We used the expression of Delilah and $\beta 1$ tubulin in the chordotonal organs as an internal control, and the intensity of staining in the EMA cells was always compared to that of the chordotonal organs (Fig. 2). Because of the dependence of the expression of Delilah and $\beta 1$ tubulin on the process of muscle-dependent differentiation of tendon cells described earlier, we suspected that the mutated locus in P1749 may be directly involved in that process. A defective differentiation of the EMA cells may lead to continuous formation of filopodia at the myotube leading edge, a phenotype characteristic of P1749.

To gain molecular insight into the gene that is defective in P1749 mutation, genomic sequences flanking the P element were rescued and used to screen an embryonic cDNA library. Several partially overlapping cDNAs were isolated and sequenced. All of the cDNAs species analyzed were identical in their sequence to *vein*, a gene described recently by Schnepf et al. (1996), which is involved in wing disc development. The hallmarks of the Vein protein demonstrated by Schnepf et al., and confirmed by our analysis, include a signal peptide at the amino-terminal domain followed by PEST sequences, an immunoglobulin-like domain, and a carboxy-terminal EGF-like domain (see Fig. 3A). Genetic evidence described in Schnepf et al. supports the idea that Vein protein complements the activity of Spitz, the major embryonic ligand of Egfr, the *Drosophila* homolog of the mammalian EGFR. Much of the regulation of the Egfr signaling cascade is thought to be controlled by the localized release of its various ligands, as Egfr is widely expressed in all germ layers throughout embryonic development (Perrimon and Perkins 1997; Schweitzer and Shilo 1997). Three putative Egfr ligands have been de-

scribed; these include two membrane-bound proteins, Spitz (Rutledge et al. 1992), Gurken (Neuman-Silberberg and Schüpbach 1993), and Vein (Schnepf et al. 1996), a neuregulin-like secreted protein. The similarity of Vein to vertebrate neuregulins (shown to bind various types of *erbB* receptors) suggests that Vein may function as a ligand of Egfr.

Several lines of evidence indicate that the *vein* gene is affected by the P1749 insertion and suggest that the defects in *vein* alone can account for the embryonic phenotype. (1) Sequence analysis of genomic sequences flanking the P1749 mutation from the proximal and distal regions indicates that the P element is inserted within the first noncoding exon of *vein* cDNA (see Fig. 3B). (2) Antibodies to Vein protein [raised against a glutathione *S*-transferase (GST)-Vein fusion protein] do not stain the P1749 mutant embryos (Fig. 4F), suggesting that Vein protein is not expressed in this mutant allele. (3) The *lacZ* expression pattern of the P element closely resembles the expression pattern of *vein* mRNA (not shown). (4) Chromosomal mapping performed using the rescued genomic DNA as a probe reveals a labeled band at chromosomal location 64F, where *vein* is mapped. This location was also confirmed with *DfXAS96* (uncovers 64E-65C1-3), which does not complement P1749. (5) Precise excision of the P element completely reverses the muscle phenotype and results in full viability of the flies, indicating that P-element insertion caused the phenotype. (6) The differentiation of the EMA cells, visualized by the levels of Delilah expression, is deranged in an ethylmethane sulfonate (EMS)-induced allele of *vein* (*vn^{dddL6}*/DfXAS96; not shown), as in the P1749 allele, verifying that this phenotype is a direct consequence of the loss of Vein functionality.

Expression of Vein during embryonic development

The expression of *vein* mRNA analyzed by in situ hybridization was described by Schnepf et al. (1996). High levels of mRNA expression are observed in somatic and visceral muscles during late stages (14–17) of embryonic development (also shown in Fig. 4A,B). To enable us to track Vein expression, antibodies were raised against a GST-Vein fusion protein. The specificity of the antibodies is verified by the following two observations: (1) Vein protein is detected when expressed in ectopic cells utilizing the Gal4/UAS expression system; and (2) no staining is detected in *vein* ($\Delta 25$ /DfXAS96) mutant embryos (Fig. 4F). Figure 4E shows an embryo expressing ectopic Vein induced by the *engrailed-gal4* inducer and stained with anti-Vein antibody. The typical *engrailed* striped expression pattern is detected with the anti-Vein antibody.

Although *vein* mRNA is prominent in the muscles (Fig. 4A,B), Vein protein expression is restricted to the sites of contact between muscles and their epidermal attachment cells (Fig. 4C,D). The pattern of staining appears to form a fine line composed of small dots. This pattern may represent small protein aggregates of Vein at the junction site. Staining is also noted along segmental

Figure 3. (A) Schematic illustration of the molecular structure of Vein. A signal peptide (SP) is present at its amino-terminal domain, followed by PEST sequences, a single immunoglobulin-like (Ig) domain, and an EGF domain at its carboxyl terminus. (B) Localization of the P1749 construct within the first noncoding exon of the *vein* gene. Solid boxes represent noncoding sequences; open boxes represent coding exons.

Figure 4. The mRNA and protein expression pattern of Vein. Wild-type embryos (A–D) were hybridized with Vein antisense probe (A,B) or with anti-Vein antibody (red in C and D). The embryo in D is double labeled for Myosin (green) and vein (red). Note that although *vein* mRNA is expressed throughout the somatic and visceral muscles, Vein protein is concentrated in the muscle–tendon junctional site (arrows in C and D). Vein protein staining is also noted in a cluster of cells along the CNS (arrowhead in C). The embryo in E labeled with anti-Vein antibody, carries *gal4* under the *engrailed* promoter and *UAS-vein*. The *engrailed* pattern is prominent. The embryo in F is a *vein*^{Δ25/DXAS96} mutant embryo labeled with anti-Vein antibody and shows no positive staining.

repeated clusters of three cells located along the central nervous system (CNS). Here too, the staining appears to be composed of small dots, but unlike the muscle–EMA junctional localization, the CNS staining seems to surround the entire cell periphery. Thus, Vein may be produced and secreted from the muscles and is localized specifically at the muscle–tendon junction sites. The mechanism of Vein localization is not known.

The protein localization of Vein at the junctional site between muscles and EMA cells, together with the abnormal muscle-dependent differentiation of the EMA cells in *vein* mutant embryo, support the possibility that Vein activity is required for tendon cell maturation.

Tendon cell differentiation in spitz group mutant embryos

The molecular structure of Vein, together with the genetic analysis performed by Schnepf et al. (1996), suggests that Vein may be an Egfr ligand. If Vein activity in tendon cell differentiation is mediated through Egfr, it is expected that this process would be abnormal in Egfr mutant embryos. We used the mutant allele *Egfr*^{1F26}, which is an embryonic lethal allele of the Egfr (at 29°C). Delilah expression in *Egfr*^{1F26} mutant embryos, deficient in Egfr, was examined. It should be noted that in *Egfr*^{1F26} mutant embryos the muscle pattern is severely disrupted. However, some of the muscles appear to be normal and to attach to EMA cells. Similarly, although the ectoderm is severely disrupted, competent EMA cells are present (not shown). *Egfr*^{1F26} mutant embryos were stained for Delilah. Whereas the expression of Delilah in the EMA cells is almost eliminated, the expression in the chordotonal organs remains high (Fig. 5A). The abnormal differentiation of tendon cells manifested by the reduced expression of Delilah is a phenotype shared by

vein and *Egfr*^{1F26} mutant embryos, supporting the possibility that Egfr is a functional receptor of Vein.

Figure 5. The expression of Delilah in *spitz* group mutant embryos. *Egfr*^{1F26} mutant embryos (A), *rho* mutant embryos (B), or *spitz* (*spi*) mutant embryos were labeled with anti-Delilah antibody. While in *rho* and *spitz* mutants, Delilah expression in the tendon cells is maintained, in the *Egfr*^{1F26} mutant, Delilah expression is significantly reduced. Compare the expression of Delilah in the EMA cells to that in the chordotonal organs (arrows).

The *spitz* group includes a number of genes [such as *Egfr*, *single-minded* (*sim*), *spitz*, *star*, *rhomboid* (*rho*), and *pointed* (*pnt*); Mayer and Nüsslein-Volhard (1988)] that affect differentiation of the ventral ectoderm. Previous analysis indicated that *Egfr* encodes for an EGF receptor homolog (Price et al. 1989; Schejter and Shilo 1989), *spi* codes for a transforming growth factor- α (TGF α) membrane-bound ligand of *Egfr* (Rutledge et al. 1992), and *rho* codes for a seven transmembrane domain protein (Bier et al. 1990) that is presumably required for Spitz processing (Schweitzer et al. 1995). To examine the possible involvement of *spi* and *rho* in tendon cell differentiation, in addition to that of *vein*, we analyzed the expression of Delilah in *spi* and *rho* mutant embryos.

Unlike the reduction of Delilah expression in *Egfr*^{1F26} mutant embryos, its expression in *spi* and *rho* mutant embryos remains high, not only in the chordotonal but also in residual EMA cells that presumably are bound to muscles (Fig. 5B,C). These results are consistent with the idea that Vein, but not Spitz, is necessary for the process of tendon cell differentiation.

Vein can induce tendon cell differentiation

The data presented above favor the possibility that Vein/*Egfr* interactions underlie the basis for muscle-dependent tendon cell differentiation. We wished to prove that Vein is not only necessary, but also sufficient, to induce Delilah expression. Because *Egfr* is expressed in all ectodermal cells and Vein is a secreted protein, we used the UAS/Gal4 expression system to express Vein in ectopic cells in the ectoderm and followed tendon-specific gene expression in those cells. Transgenic flies carrying *vein* under UAS control were produced and crossed to either a ubiquitous ectoderm Gal4 inducer (69B) or to an *engrailed-gal4* strain. Ectopic expression of Vein in the ectoderm leads to ectopic expression of Stripe, Delilah, and β 1 tubulin (Fig. 6A–D). Because Stripe is sufficient to induce Delilah and β 1 tubulin expression (Becker et al. 1997), it appears that Vein activates the expression of tendon cell-specific genes, through the induction of high levels of *stripe* transcription. The possibility that a direct activation of *delilah* transcription is also induced by ectopic Vein is not ruled out. Embryos expressing ectopic Vein under the *engrailed-gal4* inducer show a nonautonomous effect of Vein outside of the engrailed domain (Fig. 6B, in accordance with the possibility that Vein is a secreted protein and can affect neighboring cells). These results, combined with the loss-of-function phenotype of *vein* mutants, indicate that Vein/*Egfr* association mediates the muscle–EMA cell inductive interactions required for terminal differentiation of tendon cells.

Ectopic expression of Delilah induced by Vein requires *Egfr* and is mediated through the Ras pathway

The effect of ectopic Vein on Delilah expression was further used as a tool to address whether *Egfr* functions as a receptor for Vein in this process. If the effect of ectopic Vein is eliminated in the absence of *Egfr*, this

Figure 6. Ectopic expression of Vein induces ectopic expression of tendon-specific genes. Embryos carrying the UAS-*vein* construct (B–F) in combination with either the 69B-*gal4* construct (C–F) or the *engrailed-gal4* construct (B) were stained with anti-Stripe antibody (B) or with anti-Delilah antibody, or with a β 1 tubulin antisense probe. Note that ectopic Vein induces the ectopic expression of Stripe (cf. embryo in B to a wild-type embryo stained for Stripe in A). Ectopic expression of Vein also induces Delilah (C) and β 1 tubulin (D). The embryo in E carries a UAS-*vein* construct in combination with *flb*^{1F26} (null mutation for *Egfr*) and the 69B-*gal4* inducer, and was stained with anti-Delilah antibody. The ectopic expression of Delilah in this embryo is eliminated (the arrow marks the chordotonal organs). The embryo in F carries a UAS-*vein* construct in combination with the UAS-DN-*Egfr* construct and the 69B-*gal4* inducer, and is stained with anti-Delilah antibody. The ectopic expression of Delilah is significantly reduced.

would strongly favor the possibility that *Egfr* functions as a receptor for Vein in Delilah induction. To address this question, two types of embryos were constructed: (1) *Egfr*^{1F26};UAS-*vein*;gal4-69B; and (2) UAS-DN-*Egfr*;UAS-*vein*;gal4-69B (see Materials and Methods for details). In the first combination, ectopic Vein is induced in an *Egfr*^{1F26} homozygous mutant background. In the second combination, Vein is induced in embryos, whereas *Egfr* activity is reduced by the expression of the dominant-negative construct. Both of these phenotypes are coinduced only in cells where Gal4 is expressed. Mutant embryos were collected and stained for Delilah protein. No Delilah expression was detected in *Egfr*^{1F26}-ectopic Vein mutant embryos (Fig. 6E). Interestingly, in the second combination, in which DN-*Egfr* was activated by Gal4-69B, we did find embryos expressing residual ectopic Delilah (Fig. 6F). Because both UAS lines share the same Gal4 inducer, the residual ectopic expression of Delilah could be explained either by residual activity of *Egfr* and/or by the nonautonomous effect of Vein on neighboring cells expressing wild-type *Egfr*. The results

Vein induces tendon differentiation

from both experiments strongly support the possibility that Egfr is a direct receptor for Vein in the induction of EMA to tendon cell differentiation.

If Vein directly activates Egfr in the tendon cell, leading to Delilah expression, it is possible that ectopic activation of Egfr by other ligands can induce ectopic expression of Delilah. We tested whether ectopic expression of the activated form of secreted Spitz can induce Delilah expression in the ectoderm. Flies carrying the active secreted form of Spitz controlled by UAS were crossed to flies carrying the general ectoderm inducer *gal4-69B*, and their embryos were collected and stained for Delilah. The results indicate that ectopic expression of secreted Spitz induces ectopic expression of Delilah in the ectoderm (Fig. 7B).

To examine the possibility that activation of the Ras pathway is sufficient to induce Delilah expression, we expressed the activated form of Ras in the whole ectoderm. Flies carrying the activated form of Ras under UAS control were crossed to flies carrying *Gal4-69B*, and their embryos were collected and stained for Delilah. The resulting embryos show ectopic expression of Delilah (Fig. 7C).

Taken together, these experiments provide strong evidence supporting the idea that Egfr functions as the receptor for Vein in muscle-dependent tendon cell differentiation and that binding between Vein and Egfr leads

Figure 7. Activation of the Ras pathway is sufficient to induce ectopic expression of Delilah. Embryos carrying a *UAS-secreted spitz* construct (B), or *UAS-activated ras1* construct (C) in combination with the whole ectoderm *gal4* inducer *69B* were collected and stained with anti-Delilah antibody. Note that in both genetic combinations the induction of ectopic Delilah expression is prominent (cf. to the wild-type expression of Delilah shown in A).

Muscle-independent EMA gene expression

Muscle-dependent tendon cell differentiation

Figure 8. Summary of the genetic circuitry in the EMA cell before and following muscle binding. In the first phase of EMA gene expression, Stripe (Sr) activates the expression of Alien, Groovin (Grv), and low levels of Delilah (Dei) and $\beta 1$ tubulin. In the second muscle-dependent phase of gene expression, Vein/Egfr interactions activate high levels of Stripe, Groovin, Alien, Delilah, and $\beta 1$ tubulin.

to Delilah expression through activation of the Ras pathway.

Discussion

Inductive interactions performed between myotubes and their attachment cells underlie the basis for terminal differentiation of the epidermal muscle attachment cells into tendon cells. Differentiation of the EMA cells may be divided into two phases, namely muscle-independent and muscle-dependent differentiation (shown schematically in Fig. 8). In the first phase, the expression of the putative transcription factor Stripe is induced in a subset of ectodermal (EMA) cells from which tendon cells will develop. Stripe is sufficient to activate the expression of Groovin, Alien, Delilah, and $\beta 1$ tubulin. The initial low expression of Delilah and $\beta 1$ tubulin could be explained by the requirement for high levels of Stripe (which are not available initially), to activate Delilah and $\beta 1$ tubulin expression. Direct activation of $\beta 1$ tubulin by Delilah is a possibility. The presence of a putative inhibitory activity on Delilah promoter during the initial stages of EMA differentiation cannot be excluded. In addition to the activation of these genes, Stripe presumably triggers an attractive activity that guides the myotube to interact specifically with the EMA cell. The molecular nature of this activity is yet to be elucidated.

In the second muscle-dependent phase, activation of

the Egfr pathway by Vein leads to a second wave of gene expression in the EMA cells, leading to elevated levels of Stripe, Groovin, Delilah, and $\beta 1$ tubulin. Myotube binding to the EMA cell is accompanied by the formation of adherence type junctions between the two cell types. Analysis at the electron microscopy level revealed an electron-dense material deposited in the extracellular domain of these adherens type junctions (Tepass and Hartenstein 1994). It is possible that this extracellular matrix deposition is crucial for the accumulation and localization of Vein protein that is produced and secreted from the myotube at the muscle-EMA junctional site. This localization may also prevent rapid degradation of Vein protein, thereby facilitating its binding to Egfr.

Although the possibility that Egfr is the receptor for Vein was raised by Schnepf et al. (1996), the experiments in this paper provide additional evidence for this notion; in both *vein* and *Egfr^{1F26}* mutant embryos, Delilah and $\beta 1$ tubulin expression is significantly reduced, and the effect of ectopic Vein is not exerted in the absence of functional Egfr. It also appears that Vein binding to Egfr activates the Ras pathway, as ectopic expression of activated Ras could induce an effect similar to the ectopic expression of Vein. Finally, although ectopic expression of secreted Spitz leads to ectopic expression of Delilah, it appears that Spitz is not an integral part of the inductive interactions of the muscle-EMA cells, as *spitz* mutant embryos do not show reduced levels of Delilah expression. Schnepf et al. (1996) suggested that Vein might synergize with Spitz to achieve the maximal effect of Egfr activation. Our experiments indicate that Vein function in tendon cell differentiation is independent of Spitz.

Delilah appears to be a key factor in terminal differentiation of tendon cells

Previous analysis of the gene expression hierarchy in EMA cells indicated that *stripe* is a key gene in the determination of specific EMA cell fate. Stripe induces the transcription of an array of EMA-specific genes, including *groovin*, *alien*, *delilah*, and *$\beta 1$ tubulin* and possibly regulates its own transcription as well. Our results indicate that Delilah may be the key transcription factor to be activated as a result of muscle-EMA inductive interactions. The regulation of Delilah activity could occur at different levels: At the transcriptional level, it appears that only high levels of Stripe are capable of activating *delilah* transcription. At the functional level, the effect of Delilah on transcription may be modulated by the presence of additional unknown positive or negative regulators. Interestingly, the HLH inhibitory protein Extramacrochaetae (Emc) is expressed in muscle attachment cells and may counteract Delilah activity in these cells (Cubas et al. 1994). *emc* mutants also show defective muscle patterns, in line with the possibility that this protein may play a role in muscle-dependent, tendon-specific differentiation.

Additional signaling pathways, including the integrin

signaling cascade, may contribute to the differentiation process of tendon cells as well. The integrin receptors are expressed on both sides of the adherens type junctions formed between the muscles and EMA cells, and their function has been attributed mainly to the formation and maintenance of these intercellular junctions. Because vertebrate integrins have been implicated in signal transduction events, in addition to their function in mediating intercellular adhesion, it is possible that integrins at the muscle-EMA junctional site in the *Drosophila* embryo contribute to the muscle-dependent tendon cell differentiation. In that case, they may act in parallel or downstream to the Ras pathway.

Nonautonomous activation of the Ras pathway is common to various types of intercellular inductive interactions

The Ras pathway appears to be a universal signaling pathway that is continuously utilized in numerous differentiation and cell fate determination processes during embryonic development (Dickson and Hafen 1994). It has been suggested that the specific differentiation event mediated by the activation of this signaling cascade depends on the context of the cell to be triggered. An interesting functional correlation between the nonautonomous activation of the Egfr pathway by Vein and the activity of ARIA (acetylcholine receptor-inducing activity) at the site of neuromuscular synapse may be noted. Here too, a neuregulin growth factor (ARIA) is secreted from the nerve terminals to induce activation of the *erbB* receptor at the neuromuscular junction (Sanes 1997). This activation leads to elevated transcription of acetylcholine receptor in the nucleus closest to the neuromuscular synapse domain. In both examples, activation of the receptor tyrosine kinase (RTK) pathway is achieved as a result of close apposition of the two cell types.

An additional level of regulation is achieved through localization or ligand presentation. In the process of myotube-dependent tendon cell differentiation, this localization appears to be an important factor and may be regulated by an unknown matrix protein deposited at the junctional site. To this end, two mechanisms may contribute to the specific localization of Vein in the muscle-tendon junctional sites: (1) association of the protein with specific extracellular factor, and (2) rapid degradation of the protein at sites other than the junction. The PEST sequences located at the amino-terminal domain of Vein may contribute to its rapid degradation. The immunoglobulin-like domain located at the carboxyl terminus of the protein may be important for its association with other proteins at the junctional sites.

In conclusion, inductive interactions among different cell types underlie the basis for organ morphogenesis in a wide variety of species. Common signaling mechanisms, including activation of the Ras pathway in combination with other pathways, may regulate these interactions.

Materials and methods

Fly stocks

The UAS/Gal4 system used is based on Brand and Perrimon (1993). The following *gal4* inducers were used: *engrailed-gal4*, *69B-gal4* [A. Brand, Wellcome/Cancer Research Campaign (CRC) Institute, Cambridge, UK]. In addition, the following strains were used: *y w* (wild-type strain); *UAS-DN-Htl* (B. Shilo, Weizmann Institute, Rehovot, Israel); P1749 (Karpen and Spradling 1992); *Df(3L)XAS96* (W.A. Johnson, University of Iowa, Iowa City); *Egfr^{1F26}* (B. Shilo); *spitz* (N. Perrimon, Harvard Medical School, Boston, MA); *rho* (E. Bier, University of California at San Diego, La Jolla); *UAS-secreted-spitz* (B. Shilo); *UAS-ras* (C. Klamt, University of Köln, Germany). *vn^{ddl6}* (A. Simcox, Ohio State University, Columbus; A. Shearn, Johns Hopkins University, Baltimore, MD). $\Delta P25$ was produced by imprecise excision of P1749 in our laboratory. *UAS-vein* flies were constructed by ligating a 3.4-EcoRI fragment of *vein* cDNA with pUAST (Brand and Perrimon 1993), digesting with EcoRI, and introducing this construct into the fly germ line by a standard P-element transformation method. *Egfr^{1F26};UAS-vein;gal4-69B* flies were produced as follows: *Egfr^{1F26}* flies were crossed to *69B-gal4* flies to produce *Egfr^{1F26};gal4-69B* strain, and *UAS-vein* flies were crossed to *Egfr^{1F26}* to produce *Egfr^{1F26};UAS-vein*. These two strains were then crossed to produce the *Egfr^{1F26};UAS-vein;gal4-69B* flies. *Egfr^{1F26}* flies were balanced over a blue balancer, and the *Egfr^{1F26}* mutants were identified by negative β -gal staining. *UAS-DN-Egfr;UAS-vein;gal4-69B* flies were produced by crossing *UAS-DN-Egfr* flies to *UAS-vein* flies, to produce *UAS-DN-Egfr;UAS-vein* flies, and this strain was crossed with *69B-gal4* flies to produce the *UAS-DN-Egfr;UAS-vein;gal4-69B* strain. The DN-Egfr embryos were identified because of the nonretracted germ band phenotype.

Immunochemical reagents

To visualize embryonic muscles, we used anti-Myosin heavy chain polyclonal antibody, provided by P. Fisher (State University of New York, Stony Brook). The serum was usually preadsorbed on 0- to 2-hr-old embryos and diluted 1:1000 for staining. Vein was visualized either by in situ hybridization with a digoxigenin (DIG)-labeled 0.5 kb *vein* DNA fragment or by antibody against a GST-Vein fusion protein, raised in rats. The serum was diluted 1:200 for staining. Stripe was visualized with anti-GST-StripeB fusion protein raised in guinea pigs (serum dilution of 1:500), and Groovin with monoclonal anti-Groovin hybridoma supernatant (dilution of 1:2). Anti-Alien antibody was obtained from A. Paululat (University of Marburg, Germany); Delilah protein was visualized with anti-GST-Delilah fusion protein raised in rats (dilution of 1:200). β 1 tubulin expression was monitored by in situ hybridization using β 1 tubulin cDNA as a probe (D. Butgereit, University of Marburg, Germany). Anti- β -galactosidase antibodies were purchased from Cappel (USA).

Secondary antibodies included horseradish peroxidase-, fluorescein- or rhodamine-conjugated goat anti-rabbit or donkey anti-rat IgG, anti-guinea pig IgG, and anti-mouse IgM (Jackson Laboratories, USA), and anti-Dig-AP antibody (Boehringer Mannheim, Germany).

Whole-mount embryonic staining

In addition to HRP (see below) staining to determine expression of the appropriate markers, we routinely stained the embryos collected from the different mutant lines for β -galactosidase to identify homozygous mutant embryos. Staining was performed essentially as described (Ashburner 1989). In brief, embryos

were collected and incubated as indicated, dechorionated, and fixed with a mixture of 3% paraformaldehyde and heptane. Following two washes with PBT (PBS containing 0.1% Triton X-100), embryos were incubated in the X-gal staining solution until blue staining was visible (15–30 minutes at 37°C) and then washed and devitellinized with a methanol-heptane mixture. Permeabilization was performed by incubation in PBT containing 10% BSA for 2–3 hr, and incubation with primary antibody was usually performed for 16 hr at room temperature.

In situ hybridization was performed by the method of Tautz and Pfeifle (Tautz and Pfeifle 1989) with minor modifications. β -galactosidase staining, if needed, was performed before the devitellinization step. The DNA fragments used as probes were labeled by the random priming method, using DIG (Boehringer Mannheim, Germany).

Confocal microscopy

Fluorescent-labeled preparations were imaged using a Bio-Rad MRC 1024 confocal microscope coupled to a Zeiss Axiovert 135M microscope. Bright-field and fluorescent digital images were processed using Photoshop (Adobe Systems, Inc).

Cloning of vein cDNA

A 2.5-kb plasmid rescue DNA fragment was used to screen a partial EcoRI-restricted *Drosophila* genomic library (Levine et al. 1994). A single genomic clone of ~30 kb in length was isolated. Genomic DNA fragments on both sides of the P element were analyzed by in situ hybridization. A 0.5-kb genomic fragment gave a similar pattern of expression as the *lacZ* pattern of the original P-element mutation and therefore was used to screen an embryonic (9–12 hr) *Drosophila* λ gt11 cDNA library (Zinn et al. 1988). Several clones were isolated, all of which correspond to partial overlapping sequences. Sequence analysis of the cDNAs isolated revealed that the gene isolated is identical to *vein*. Sequencing was performed by an automated sequencer (Applied Biosystems). The sequences were analyzed by AutoAssembler DNA sequence assembly software package (v. 1.0.3; Applied Biosystems). The predicted amino acid sequences were analyzed by the program package of the University of Wisconsin Genetics Computer Group (UWGCG; v. 8.1-UNIX). We searched the nonredundant GenBank, PIR, and EMBL databases with Vein amino acid sequence using the Mail Server Utility (MSU, v. 1.4), choosing various programs to identify the various conserved domains. The MOTIFS program of the UWGCG package was used for identification of putative post-translational modifications. Additional potential post-translational modifications were identified manually.

Acknowledgments

We thank A. Brand, E. Hafen, B. Shilo, C. Klamt, A. Simcox, and A. Shearn for various fly strains; P. Fisher, D. Butgereit, and M. Cole for antibodies and cDNA probes; B. Shilo and S. Schwarzbaum for critical reading of the manuscript and helpful comments; M. Krasnow for making the collection of embryos from the lethal P-element screen available to us; and S. Becker for making the anti-Delilah antibody. This work was supported by a grant from the Israel Cancer Research Fund (T.V.).

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Abmayr, S.M., M.S. Erickson, and B.A. Bour. 1995. Embryonic development of the larval body wall musculature of *Drosophila melanogaster*. *Trends Genet.* **11**: 153–159.
- Armand, P., A.C. Knapp, A.J. Hirsch, E.F. Wieschaus, and M.D. Cole. 1994. A novel basic helix-loop-helix protein is expressed in muscle attachment sites of the *Drosophila* epidermis. *Mol. Cell. Biol.* **14**: 4145–4154.
- Ashburner, M. 1989. *Drosophila: A laboratory manual*, pp 44–49. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY.
- Azpiazu, N., P.A. Lawrence, J.P. Vincent, and M. Frasch. 1996. Segmentation and specification of the *Drosophila* mesoderm. *Genes & Dev.* **10**: 3183–3194.
- Baker, R. and G. Schubiger. 1995. Ectoderm induces muscle-specific gene expression in *Drosophila* embryos. *Development* **121**: 1387–1398.
- Bate, M. 1990. The embryonic development of larval muscles in *Drosophila*. *Development* **110**: 791–804.
- . 1993. The mesoderm and its derivatives. In *The development of Drosophila melanogaster* (ed. M. Bate and A. Martinez Arias), pp. 1013–1090. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Baylies, M.K. and M. Bate. 1996. *twist*: A myogenic switch in *Drosophila*. *Science* **272**: 1481–1484.
- Becker, S., G. Pasca, D. Strumpf, L. Min, and T. Volk. 1997. Reciprocal signaling between *Drosophila* epidermal muscle attachment cells and their corresponding muscles. *Development* **124**: 2615–2622.
- Bier, E., L.Y. Jan, and Y.N. Jan. 1990. *rhomboid*, a gene required for dorsoventral axis establishment and peripheral nervous system development in *Drosophila melanogaster* [published erratum appears in *Genes & Dev.* 1990 **4**: 680–681]. *Genes & Dev.* **4**: 190–203.
- Birchmeier, C., D. Meyer, and D. Riethmacher. 1995. Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. *Int. Rev. Cytol.* **160**: 221–266.
- Brand, A.H. and N. Perrimon. 1993. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**: 401–415.
- Buttgereit, D., A. Paululat, and R. Renkawitz Pohl. 1996. Muscle development and attachment to the epidermis is accompanied by expression of beta 3 and beta 1 tubulin isoforms, respectively. *Int. J. Dev. Biol.* **40**: 189–196.
- Cubas, P., J. Modolell, and M. Ruiz Gomez. 1994. The helix-loop-helix extramacrochaetae protein is required for proper specification of many cell types in the *Drosophila* embryo. *Development* **120**: 2555–2566.
- Dickson, B. and E. Hafen. 1994. Genetics of signal transduction in invertebrates. *Curr. Opin. Genet. Dev.* **4**: 64–70.
- Frommer, G., G. Vorbruggen, G. Pasca, H. Jäckle, and T. Volk. 1996. Epidermal egr-like zinc finger protein of *Drosophila* participates in myotube guidance. *EMBO J.* **15**: 1642–1649.
- Goubeaud, A., S. Knirr, R. Renkawitz-Pohl, and A. Paululat. 1996. The *Drosophila* gene *alien* is expressed in the muscle attachment sites during embryogenesis and encodes a protein highly conserved between plants, *Drosophila* and vertebrates. *Mech. Dev.* **57**: 59–68.
- Karpen, G.H. and A.C. Spradling. 1992. Analysis of subtelomeric heterochromatin in the *Drosophila* minichromosome Dp1187 by single P element insertional mutagenesis. *Genetics* **132**: 737–753.
- Lee, J.C., K. VijayRaghavan, S.E. Celniker, and M.A. Tanouye. 1995. Identification of a *Drosophila* muscle development gene with structural homology to mammalian early growth response transcription factors. *Proc. Natl. Acad. Sci.* **92**: 10344–10348.
- Levine, A., A. Bashan Ahrend, O. Budai Hadrian, D. Gartenberg, S. Menasherow, and R. Wides. 1994. Odd Oz: A novel *Drosophila* pair rule gene. *Cell* **77**: 587–598.
- Mayer, U. and C. Nüsslein-Volhard. 1988. A group of genes required for pattern formation in the ventral ectoderm of the *Drosophila* embryo. *Genes & Dev.* **2**: 1496–1511.
- Neuman-Silberberg, F.S. and T. Schüpbach. 1993. The *Drosophila* dorsoventral patterning gene *gurken* produces a dorsally localized RNA and encodes a TGF alpha-like protein. *Cell* **75**: 165–174.
- Perrimon, N. and L. A. Perkins. 1997. There must be 50 ways to rule the signal: The case of the *Drosophila* EGF receptor. *Cell* **89**: 13–16.
- Price, J.V., R.J. Clifford, and T. Schupbach. 1989. The maternal ventralizing locus *torpedo* is allelic to faint little ball, an embryonic lethal, and encodes the *Drosophila* EGF receptor homolog. *Cell* **56**: 1085–1092.
- Rushon, E., R. Drysdale, S.M. Abmayr, A.M. Michelson, and M. Bate. 1995. Mutations in a novel gene, myoblast city, provide evidence in support of the founder cell hypothesis for *Drosophila* muscle development. *Development* **121**: 1979–1988.
- Rutledge, B.J., K. Zhang, E. Bier, Y.N. Jan, and N. Perrimon. 1992. The *Drosophila* *spitz* gene encodes a putative EGF-like growth factor involved in dorsal-ventral axis formation and neurogenesis. *Genes & Dev.* **6**: 1503–1517.
- Sanes, J.R. 1997. Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction. *Curr. Opin. Neurobiol.* **7**: 93–100.
- Schejter, E.D. and B.Z. Shilo. 1989. The *Drosophila* EGF receptor homolog (DER) gene is allelic to faint little ball, a locus essential for embryonic development. *Cell* **56**: 1093–1104.
- Schnepp, B., G. Grumblin, T. Donaldson, and A. Simcox. 1996. Vein is a novel component in the *Drosophila* epidermal growth factor receptor pathway with similarity to the neuregulins. *Genes & Dev.* **10**: 2302–2313.
- Schweitzer, R. and B.Z. Shilo. 1997. A thousand and one roles for *Drosophila* EGF receptor. *Trends Genet.* **13**: 191–196.
- Schweitzer, R., M. Shaharabany, R. Seger, and B.Z. Shilo. 1995. Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination. *Genes & Dev.* **9**: 1518–1529.
- Tautz, D. and C. Pfeifle. 1989. A non-radioactive in situ hybridization method for the localization of specific RNAs in *Drosophila* embryos reveals translational control of the segmentation gene *hunchback*. *Chromosoma* **98**: 81–85.
- Tepass, U. and V. Hartenstein. 1994. The development of cellular junctions in the *Drosophila* embryo. *Dev. Biol.* **161**: 563–596.
- Volk, T. and K. VijayRaghavan. 1994. A central role for epidermal segment border cells in the induction of muscle patterning in the *Drosophila* embryo. *Development* **120**: 59–70.
- Zinn, K., L. McAllister, and C.S. Goodman. 1988. Sequence analysis and neuronal expression of fasciclin I in grasshopper and *Drosophila*. *Cell* **53**: 577–587.

The *Drosophila* neuregulin homolog Vein mediates inductive interactions between myotubes and their epidermal attachment cells

Talia Yarnitzky, Li Min and Talila Volk

Genes Dev. 1997, 11:

Access the most recent version at doi:[10.1101/gad.11.20.2691](https://doi.org/10.1101/gad.11.20.2691)

References

This article cites 33 articles, 17 of which can be accessed free at:
<http://genesdev.cshlp.org/content/11/20/2691.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).